Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2025-02-07 Regulatory Filings
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document contains multiple public notices related to the enforcement of security interests under the Securitization and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 (SARFAESI Act). It includes possession notices, substituted service of notices, and demand notices for repayment of loans, with detailed descriptions of immovable properties and legal references to the SARFAESI Act. There is no indication of financial statements, management discussion, earnings data, or other typical financial report content. The document is a regulatory announcement of legal and enforcement actions by financial institutions regarding loan defaults and asset possession. Therefore, it fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit into other specific categories like Audit Report, Annual Report, or Legal Proceedings Report (which would require more detailed litigation information). The document length is substantial and contains detailed notices, not just a brief announcement or certification, so it is not RPA or a certification. Confidence is high due to the clear legal and regulatory nature of the notices.
2025-02-07 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Notice of Postal Ballot issued by Beta Drugs Limited, dated February 6, 2025. It includes detailed information about resolutions proposed to be passed by shareholders through remote e-voting, including increase in authorized share capital, issue of bonus shares, and appointment of independent directors. The document references compliance with the Companies Act, SEBI regulations, and other legal provisions. It is a formal communication to shareholders seeking their approval on corporate actions via postal ballot. This type of document is neither a full financial report nor a simple announcement of a report. It is a solicitation for shareholder voting on corporate governance and capital structure matters. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings or resolutions.
2025-02-06 English
General Updates
Board/Management Information Classification · 95% confidence The document is a letter responding to a regulatory observation regarding a previous announcement about the appointment of directors. It confirms that the appointed directors are not debarred by any authority. The document is short (1194 characters) and does not contain any financial data or detailed report content. It is related to board/management changes but is not the announcement itself, rather a regulatory response or clarification. Therefore, it fits best under Board/Management Information (MANG) as it pertains to director appointments and related confirmations.
2025-02-06 English
Outcome of Board Meeting
Regulatory Filings
2025-02-05 English
Bonus
Regulatory Filings
2025-02-05 English
Bonus
Regulatory Filings
2025-02-05 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.